The Study of NT-proBNP Combined With HS-cTnT in Evaluating the Prognosis of Sepsis

NCT04963699 | Completed

• 1 other identifier: 2021-0317
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

To study the clinical value of combined detection of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-cTnT) in assessing the prognosis of patients with sepsis. Methods Seventy-three patients with sepsis who were diagnosed and treated in our hospital from June 2016 to March 2021 were divided into general sepsis group and severe sepsis group. According to different outcomes, they were divided into survival Group and death group, to explore the relationship between plasma NT-proBNP, hs-cTnT levels and APACHEⅡ score and the value of prognostic evaluation of sepsis.

Conditions

Sepsis

Keywords

N-terminal pro-brain natriuretic peptide; High-sensitivity troponin T

Outcome Measures

Primary Outcomes (3)

• NT-proBNP

  NT-proBNP is used as an aid to diagnose and monitor mild cardiac dysfunction in individuals suspected of having congestive heart failure. Compared with BNP, NT-proBNP has a longer half-life, better stability, and higher plasma concentration. , Has superiority in predicting myocardial function. Studies have found that NT-proBNP can be used as an important indicator for the prognosis of sepsis with impaired cardiac function and sepsis.The higher the plasma concentration of NT-proBNP, the worse the prognosis.

  2016.06.01-----2021.03.30

• hs-cTnT

  hs-cTnT is an independent prognostic marker that can predict the short-term, mid-term and even long-term outcomes of patients with acute coronary syndrome (ACS). Patients with sepsis often have different degrees of damage to myocardial cells, and their plasma hs-cTnT concentration will also increase to different degrees.

  2016.06.01-----2021.03.30

• APACHEⅡ score

  During the diagnosis and treatment of sepsis, the APACHE II score can be used to assess the severity of the patient's condition, and is also of important value for the patient's prognostic effect. The higher the score, the more severe the condition.

  2016.06.01-----2021.03.30

Eligibility Criteria

• Age: 16 Years - 89 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with sepsis who were diagnosed and treated in our hospital from June 2016 to March 2021

You may qualify if:

• All have clear infection through clinical examination; no acute coronary syndrome, no immunodeficiency, no tumor, etc. in the past 1 month; no pulmonary embolism or aortic dissection; no valvular heart disease, cardiomyopathy, myocarditis, etc.; no pregnant women And lactating women; no congenital heart, liver, kidney and other organ diseases.

You may not qualify if:

• Acute coronary syndrome, immunodeficiency, tumor, etc. in the past month; pulmonary embolism and aortic dissection; valvular heart disease, cardiomyopathy, myocarditis, etc.; pregnant and lactating women; congenital Heart, liver, kidney and other organ diseases

Sponsors & Collaborators

• Second Affiliated Hospital, School of Medicine, Zhejiang University: lead

Study Sites (1)

Roche 601 Biochemical Immunoassay Instrument

Hangzhou, Zhejiang, 310000, China

Location

MeSH Terms

Conditions

Sepsis

Condition Hierarchy (Ancestors)

Infections; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• yang xufeng, MS

  Second Affiliated Hospital, School of Medicine, Zhejiang University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 9, 2021
• First Posted: July 15, 2021
• Study Start: May 26, 2021
• Primary Completion: June 2, 2021
• Study Completion: June 9, 2021
• Last Updated: July 15, 2021

Record last verified: 2016-06

Locations

CN (1)